Glioblastoma
Conditions
Keywords
Glioblastoma, Brain Tumor
Brief summary
The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
Detailed description
The objective of this proposed study is to determine the expression levels of a panel of markers including CD133, CD44, ABCC3, TNFRSF1A, AKT1, IDH2, and MGMT in GBM tissues and the CSF, blood, and saliva from patients with GBM receiving different types of treatment (Optune only or Optune with TMZ) and the non-brain tumor patients (controls). Our aims are: 1) To compare the differences of CD44 between the control group and the combined cancer groups at baseline; and 2) To compare the levels of CD44 and other markers among the 3 different groups such as control vs. GBM patients and Optune vs. Optune + TMZ after 8 weeks of treatment. Exploratory analysis of all other markers will be performed.
Interventions
DEVICEOptune
Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located. TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.
Sponsors
Baylor Research Institute
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 22 years old * Control Group (only patients evaluated for neurological disorders whose evaluation require a lumbar puncture) * Non-Control Group - Diagnosed with GBM (Glioblastoma)
Exclusion criteria
* Pregnancy * Infectious Disease to include cold, flu, HIV, etc. * Blood Disorder (example:low platelets, anemia, thrombosis) * Vascular Malformations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome - CD44 expression in cerebrospinal fluid (CSF), blood and saliva | 2 years | Currently, Glioblastoma is only diagnosed and monitored with brain scans. Expression levels of CD44 along with CD133, ABCC3, TNFRSF1A, AKT1, IDH2 and MGMT in samples of CSF, blood and saliva from patients receiving different types of treatment and comparing them with non-GBM patients (control group) will be tested. |
Countries
United States
Outcome results
None listed